Table 3.
Comparison of the outcomes reported in the non-stenting medical treatment only arms of the SAMMPRIS and VISSIT trials with comparable outcomes in OXVASC cohort categorised by 50-99% and 70-99% symptomatic intracranial stenosis (ICS).
| SAMMPRIS 2-year outcomes* | VISSIT 1-year outcomes | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| ||||||||||||
| Any stroke/ death <30d and same territory IS >30d | Any stroke or death | Any stroke | Same territory IS or hard TIA (>2d) | Same territory IS | Any territory hard TIA (>2d) | |||||||
|
| ||||||||||||
| Events | Risk (95% CI) | Events | Cum. risk (95% CI) | Events | Cum. risk (95% CI) | Events | Cum. risk (95% CI) | Events | Cum. risk (95% CI) | Events | Cum. risk (95% CI) | |
| SAMMPRIS (n= 227) | 34 | 14.1 % (10.1-19.4) | 51 | 19.8% (15.1-25.6) | 13 | 17.2% (12.9-22.9) | - | |||||
| VISSIT (n= 53) | - | 8 | 15.1% (6.7-27.6) | 5 | 9.4% (3.1-20.7) | 3 | 5.7% (1.2-15.7) | |||||
| OXVASC (1) (n= 94) | 8 | 9.0% (2.9-15.1) | 21 | 23.4% (14.6-32.2) | 9 | 10.8% (3.9-17.7) | 11 | 12.0% (5.3-18.7) | 5 | 5.5% (0.8-10.2) | 7 | 7.6% (2.1-13.1) |
| OXVASC (2) (n= 74) | 6 | 8.2% (1.9-14.5) | 16 | 22.6% (12.8-32.4) | 6 | 8.9% (2.0-15.8) | 8 | 11.1% (3.9-18.4) | 4 | 5.6% (0.3-11.1) | 5 | 6.9% (1.0-12.8) |
| OXVASC (3) (n= 36) | 2 | 5.6% (0.0-13.0) | 8 | 22.7% (8.8-36.6) | 3 | 9.2% (0.0-19.2) | 5 | 13.9% (2.5-25.3) | 2 | 5.6% (0.0-13.0) | 3 | 8.3% (0.0-17.3) |
(1) All OXVASC 50-99% symptomatic ICS
(2) OXVASC 50-99% symptomatic ICS excluding atrial fibrillation
(3) OXVASC 70-99% symptomatic ICS fulfilling trial criteria
*
Any stroke= ischaemic stroke (IS), intracerebral haemorrhage or subarachnoid haemorrhage